<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04021069</url>
  </required_header>
  <id_info>
    <org_study_id>270-2018</org_study_id>
    <nct_id>NCT04021069</nct_id>
  </id_info>
  <brief_title>Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer</brief_title>
  <official_title>Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines retrospective clinical data on patients diagnosed with breast cancer and
      monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence,
      distant metastasis, and disease-free survival. The hypothesis of this study is that breast
      cancer patients who achieve a pathological complete response (pCR) to neoadjuvant
      chemotherapy demonstrate distinct clinicopathomic biomarker signatures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of the study are to (1) to identify clinicopathomic biomarkers from
      pre-treatment core biopsies that are predictive of response to neoadjuvant chemotherapy, (2)
      determine patterns of metastasis from primary breast cancer to other distant sites, (3)
      determine the rates of local recurrence in breast cancer patients, and (4) to determine if
      there are significant radiomic, pathomic, and clinical markers for recurrence and distant
      metastasis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response (pCR)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Evaluating the degree of absence of residual cancer cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to local breast recurrence</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Evaluating the time until a recurrence event has occurred in the breast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant metastasis (months)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Evaluating onset of distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Evaluating time to cancer-related death</description>
  </secondary_outcome>
  <enrollment type="Actual">800</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Invasive Ductal Breast Carcinoma</condition>
  <condition>Invasive Lobular Breast Carcinoma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Radiomic, pathomic, and clinical markers</intervention_name>
    <description>This is a non-interventional study.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fixed tissue samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll women and men with a pathologically-confirmed diagnosis of invasive
        breast cancer of any stage, according to the AJCC v7 criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be men and women age 18+

          -  Biopsy-confirmed diagnosis of invasive breast cancer; (ER+/-, PR+/-, HER2+/-)

          -  Any state of disease as described by AJCC v7 criteria

          -  Participants must have received and completed neoadjuvant chemotherapy

        Exclusion Criteria:

          -  Participants who had other primary cancers prior to breast cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William T. Tran, MRT(T), PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kasia Jerzak, M.Sc., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fang-I Lu, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>July 12, 2019</last_update_submitted>
  <last_update_submitted_qc>July 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. William Tran</investigator_full_name>
    <investigator_title>Radiation Therapist Clinician Scientist</investigator_title>
  </responsible_party>
  <keyword>radiomics</keyword>
  <keyword>pathomics</keyword>
  <keyword>breast cancer</keyword>
  <keyword>machine learning</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
    <mesh_term>Carcinoma, Lobular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data will be anonymized. Digital pathology images and anonymized clinical data will be deposited into the National Cancer Institute (NCI) data sharing repository, including The Cancer Imaging Archive (TCIA). Digital pathology images will also be annotated to facilitate analysis for other investigators. Computational methods, source-codes and instructions will be deposited to the open-source coding repository, GitHub (www.github.com).</ipd_description>
    <ipd_time_frame>Data will be available within 12 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Digital pathology images, anonymized clinical data, source codes, and computational methods will be deposited to open-source repositories.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

